18F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer

Title
18F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer
Other Titles
18F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer
Author(s)
천경아공은정조인호이수정
Keywords
Breast cancer - Axillary lymph node - FDG - PET/CT; Breast cancer - Axillary lymph node - FDG - PET/CT
Issue Date
201009
Publisher
대한핵의학회
Citation
Nuclear Medicine and Molecular Imaging, v.44, no.3, pp.170 - 176
Abstract
Background 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography ((PET) safely predicts axillary status in patients with breast cancer, but is not sufficiently accurate in early breast cancer patients. This study analyzed the value of 18F-FDG PET/computed tomography (CT) with contrast enhancement in detecting axillary lymph node involvement in T1 breast cancer patients. Methods Contrast-enhanced 18F-FDG PET/CT was performed within 20 days of surgery in 143 breast cancer patients with tumors ≤2 cm in size. The patients underwent either axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB), and histopathology reports were used to provide the definitive diagnosis against which the contrast-enhanced 18F-FDG PET/CT study results were compared. Results The sensitivity, specificity, and negative and positive predictive values of contrast-enhanced 18F-FDG PET/CT in detecting axillary involvement were 70.0%, 92.2%, 88.8%, and 77.8%, respectively, in the entire series of 143 patients, with eight false-positive and 12 false negative results. The false-negative results were associated with the number of metastatic lymph nodes and the rate of FDG uptake. Conclusion Contrast-enhanced 18F-FDG PET/CT cannot replace histologic staging using SLNB in patients with breast cancer, but 18F-FDG PET/CT increases the sensitivity for predicting axillary node metastasis, and allows for a selective approach to either ALND or SLNB, even in patients with T1 breast cancer.
URI
http://hdl.handle.net/YU.REPOSITORY/23605
ISSN
1869-3474
Appears in Collections:
의과대학 > 핵의학교실 > Articles
의과대학 > 성형외과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE